'Blood use in intensively treated AML patients in the Netherlands'

Aims: -Describe differences in blood use in trials between centers and treatment arms (RBC, PLT, plasma)

-Describe differences in transfusion triggers between centers

-Generate evidence for best/ practical transfusion guidelines for studies and daily practice (baseline measurement)

Patients: -AML patients in HOVON 29, 42, 92 or 102 in NL, at least 2 courses of chemotherapy + CR1 after one or two courses

Methods: -Retrospective observational research

-HOVON database, clinical chemistry/transfusion labs

Status: -@ Medical Ethical Board LUMC

-Expected start of data collection Q4 2017

Your participation will be greatly appreciated!